NCT05701007Completed
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions: * What are the demographic and clinical characteristics of metastatic prostate cancer patients? * How are metastatic prostate cancer patients currently treated and how effective are these treatments? * How does the development of castration-resistance affect patient outcomes? * What is the economic burden of metastatic prostate cancer?
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1083 (actual)
- First submitted
- 17 Jan 2023
- Start date
- Feb 2023
- Primary completion date
- Apr 2024
- Lead sponsor
- Pfizer
- Diseases
- Prostate cancer
- NCT number
- NCT05701007
What you commit to
- Study type: Observational
- Participants enrolled: 1083
- From Feb 2023 to the primary completion date, Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient has another cancer diagnosis or the patient has received chemotherapy other than docetaxel or cabazitaxel within 2 years of mPC diagnosis.
Other
- Prevalent mCSPC and mCRPC patients (mCSPC or mCRPC diagnosis date before 1/1/2014
Who the study is looking for
- Diagnosis of prostate cancer between 1/1/2007 - 12/31/2022
- Resident of Pirkanmaa at index date (diagnosis of mCSPC and/or mCRPC)
- Detection of metastatic prostate cancer
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | Helsinki | Finland | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.